WHO/EU GDP (Pharma)

WHO/EU Good Distribution Practice (GDP)

Safeguard Pharmaceutical Quality Through the Entire Supply Chain
Good Distribution Practice (GDP) ensures that the quality and integrity of medicines are maintained throughout the supply chain—from the manufacturer to the patient. Based on WHO and EU guidelines, this standard is critical for preventing counterfeiting and ensuring temperature control. At MFT Global Consultancy, we help you implement a compliant GDP system that meets the strict requirements of health authorities globally.

Book Your Consultation Book Your Consultation Book Your Consultation

Who Needs GDP Certification & Compliance?

This is mandatory for any organization involved in the storage, transportation, or trade of pharmaceutical products. We support the pharma supply chain across the UAE, KSA, Australia, and New Zealand, complying with local bodies (like MOHAP and SFDA) and international standards:

Pharmaceutical Wholesalers & Distributors

Logistics & Transport Companies (Cold Chain)

Warehousing & Storage Facilities

Pharmacies & Hospital Chains

Medical Importers & Exporters

Key Benefits of WHO/EU GDP Compliance?

Patient Safety First

Ensure that the medicines reaching the patient are safe, effective, and have not been compromised by poor storage or temperature excursions.

Regulatory Compliance

Meet the stringent requirements of local health authorities (such as the UAE Ministry of Health or Saudi FDA) and align with EU/WHO global standards.

Cold Chain Integrity

Implement robust temperature mapping and monitoring systems to ensure heat-sensitive products (like vaccines and insulin) remain viable.

Anti-Counterfeiting Measures

Secure your supply chain against falsified medicines. GDP provides the traceability and documentation needed to prove product authenticity.

Global Market Access

Export with confidence. Compliance with EU GDP guidelines is often a prerequisite for trading pharmaceuticals with European and international partners.

Reduced Wastage

Minimize financial losses caused by spoiled stock, improper handling, or rejected shipments through standardized operational procedures.

Fast-Track Your Pharma GDP Compliance